The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ± pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric or gastroesophageal junction cancer: DESTINY-Gastric05
Kohei Shitara
View presentation
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
Gastric Cancer
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy ± pembrolizumab versus chemotherapy + trastuzumab ± pembrolizumab in first-line metastatic HER2+ gastric or gastroesophageal junction cancer: DESTINY-Gastric05
Kohei Shitara
View presentation
Poster
T-DXd
ASCO 2025 | May 30-June 3,2025
Gastric Cancer
ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan as first-line treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer
Rui-Hua Xu
View presentation
Poster
T-DXd
JSMO 2025 | March 6-8, 2025
Gastric Cancer
Efficacy of trastuzumab deruxtecan and biomarker changes in HER2-positive gastric cancer: EN-MARK study protocol
Akira Ooki
View presentation
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study
Kohei Shitara
View presentation
Poster
T-DXd
ESMO Asia 2025 | December 5-7, 2025
Gastric Cancer
First-line trastuzumab deruxtecan 5.4 mg/kg and fluoropyrimidine with pembrolizumab in advanced HER2+ gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Updated results from DESTINY-Gastric 03 part 2F
Yelena Y. Janjigian
View presentation
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
First-line trastuzumab deruxtecan with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: DESTINY-Gastric03 part 5
Yelena Y. Janjigian
View presentation
Poster
T-DXd
ASCO GI 2026 | January 8-10, 2026
Gastric Cancer
GEMINI-PeriOp Gastric: A phase 2 study of novel agent-based combinations as perioperative therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction, or esophageal adenocarcinoma
Ziyu Li
View presentation
Mini-Oral
T-DXd
JSMO 2025 | March 6-8, 2025
Gastric Cancer
Prognostic factors for T-DXd treatment in HER2+ unresectable advanced/recurrent gastric cancer: EN-DEAVOR sub-analysis
Naotoshi Sugimoto
View presentation
Poster
R-DXd
ESMO 2025 | October 17-21, 2025
Gastric Cancer
Raludotatug deruxtecan in participants with gastrointestinal cancers: Phase 2 REJOICE-GI01 trial
Makoto Ueno
View presentation
Pages: 1  2  
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24